0001209191-18-037121.txt : 20180611
0001209191-18-037121.hdr.sgml : 20180611
20180611193151
ACCESSION NUMBER: 0001209191-18-037121
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180607
FILED AS OF DATE: 20180611
DATE AS OF CHANGE: 20180611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MECHEM KRISTINE C.
CENTRAL INDEX KEY: 0001662454
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37648
FILM NUMBER: 18893249
MAIL ADDRESS:
STREET 1: 1301 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoCyte Corp
CENTRAL INDEX KEY: 0001642380
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 271041563
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
BUSINESS PHONE: 510-775-0515
MAIL ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-07
0
0001642380
OncoCyte Corp
OCX
0001662454
MECHEM KRISTINE C.
1010 ATLANTIC AVENUE
SUITE 102
ALAMEDA
CA
94501
0
1
0
0
VP of Marketing
Option to Purchase Common Stock
2.85
2018-06-07
4
A
0
50000
0.00
A
2028-06-06
Common Stock
50000
50000
D
Option to Purchase Common Stock
2.35
2028-05-22
Common Stock
125000
125000
D
Option to Purchase Common Stock
4.70
2027-02-16
Common Stock
67500
67500
D
Option to Purchase Common Stock
3.06
2026-02-15
Common Stock
60000
60000
D
Option to Purchase Common Stock
3.16
2025-08-03
Common Stock
100000
100000
D
One half of these options shall vest on the filing of the Medicare dossier for the Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date, and the balance shall vest on the date of return from sabbatical and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate, subject to continuous employment on such date.
These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
One quarter of the options vested on February 16, 2018, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
One quarter of the options vested on August 3, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
/s/Kristine C. Mechem
2018-06-11